Serious adverse events ( · children with either displaced distal radius fracture with intact or displaced ulna fracture (both‐bone fracture), or minimally displaced…
1 finding from 1 review
Serious adverse events ( · Individuals with peripheral arterial disease
Growth factors showed no clear difference in serious adverse events ( compared with placebo or no therapy (moderate certainty).
1 finding from 1 review
Serious adverse eventsc ( · adult patients after liver transplantation.
Prostaglandin showed no clear difference in serious adverse eventsc ( compared with placebo or standard care (low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events2,4 · Patients with advanced non‐small cell lung cancer
The intervention may leads to higher serious adverse events2,4 (low certainty).
1 finding from 1 review
RR 37.36 [10.66, 130.95]
1 study · 4 participants
Low
Non‐serious adverse events · farmworkers
It is very uncertain whether summary of findings table ‐ Antibiotics changes non‐serious adverse events compared with other antibiotics (very low certainty).
1 finding from 1 review
Non‐serious adverse events · farmworkers, soldiers, and people in endemic areas
It is very uncertain whether summary of findings table ‐ Antibiotics changes non‐serious adverse events compared with placebo or no intervention (very low certainty).
1 finding from 1 review
All serious adverse events · adults with acute spontaneous intracerebral haemorrhage
Summary of findings table ‐ Antifibrinolytic drug(s) showed no clear difference in all serious adverse events compared with placebo/open control (high certainty).
1 finding from 1 review
All serious adverse events · adults with acute spontaneous intracerebral haemorrhage associated with antiplatelet drug use
Summary of findings table ‐ Platelet transfusion showed no clear difference in all serious adverse events compared with open control (moderate certainty).
1 finding from 1 review
All serious adverse events · adults with acute spontaneous intracerebral haemorrhage associated with anticoagulant drug use
It is very uncertain whether summary of findings table ‐ Prothrombin complex concentrates changes all serious adverse events compared with fresh frozen plasma (very low certainty).
1 finding from 1 review
RR 0.27 [0.02, 3.74]
1 study · 5 participants
Very low
All serious adverse events · adults with acute spontaneous intracerebral haemorrhage
It is very uncertain whether summary of findings table ‐ Recombinant activated factor VII changes all serious adverse events compared with placebo/open control (very low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse eventsLast · people with degenerative knee disease (osteoarthritis including degenerative meniscal tears)
The intervention showed no clear difference in serious adverse eventsLast (low certainty).
1 finding from 1 review
All serious adverse events · children
Rotarix leads to lower all serious adverse events compared with placebo (high certainty).
3 findings from 1 review
RR 0.85 [0.76, 0.95]
9 studies · 77069 participants
High
RR 0.9 [0.77, 1.05]
10 studies · 7674 participants
High
RR 0.89 [0.72, 1.1]
12 studies · 18971 participants
High
All serious adverse events · children
RotaTeq showed no clear difference in all serious adverse events compared with placebo (high certainty).
3 findings from 1 review
RR 0.92 [0.84, 1.01]
5 studies · 70690 participants
High
RR 0.66 [0.14, 3.17]
2 studies · 4082 participants
Very low
RR 0.99 [0.72, 1.36]
4 studies · 7730 participants
Moderate
All serious adverse events · children
Rotasiil showed no clear difference in all serious adverse events compared with placebo (high certainty).
1 finding from 1 review
All serious adverse events · children
Rotavac showed no clear difference in all serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Non‐serious adverse events · people with chronic liver diseases
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Non‐serious adverse events · people with resectable cholangiocarcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Non‐serious adverse events · people with Duchenne muscular dystrophy and progressive respiratory decline
Idebenone showed no clear difference in non‐serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Non‐serious adverse events · people with hepatocellular carcinoma
1 finding from 1 review
Non‐serious adverse events · primary prophylaxis of oesophageal variceal bleeding in children with chronic liver disease or portal vein thrombosis
1 finding from 1 review